HTAi Program at a Glance As of February 14, 2014



HTAI 2014 ANNUAL MEETING WORKSHOPS AND PANEL SESSIONS

DAY 1 - SATURDAY, JUNE 14 (click here)

9:00 - 17:00

WS05: Capacity building for information retrieval for health technology assessments

(HTA)

Sari Susanna Ormstad, Norway Carol Lefebvre, United Kingdom Ingrid Harboe, Norway David Kaunelis, Canada

13:30 - 17:00

WS01: HTA 101: Introduction to Health Technology Assessment

Clifford Goodman, USA

WS03: Capacity building in agencies for efficient and effective HTA

Debjani Mueller, Denmark **Iñaki Gutierrez-Ibarlueza**, Spain **Tara Schuller**, Canada WS04: Analytical decision models for HTA: how to choose a distribution for my probabilistic sensitivity analysis? Examples from mental health data

Luciane N. Cruz, Brazil
Ana Flavia S. Lima, Brazil
Patricia K. Ziegelmann, Brazil
Steffan F. Stella, Brazil
Patricia C. Soárez, Brazil
Carisi A. Polanczyk, Brazil

DAY 2 - SUNDAY, JUNE 15 (click here)

9:00 - 12:30

WS06: Introduction to Ethics in Health Technology Assessment

Bjørn Hofmann, Norway Wija Oortwijn, The Netherlands Anna Stoklosa, Australia Ken Bond, Canada Dario Sacchini, Italy

WS09: Implementing Principles and Quality Standards for Patient Engagement in HTA -

A Journey together

Janet L. Wale, Australia Karen Facey, Scotland Kin Ping Tsang, Hong Kong Elaine McPhail, Canada Ann Single, Australia

9:00 - 17:00

WS07: HTA 101: Introduction to Health Technology Assessment

Marco Marchetti, Italy
Americo Cicchetti, Italy
Marco Oradei, Italy
Carmen Furno, Italy
Rossella Di Bidino, Italy

WS08: Using Mechanistic Evidence for HTA

Tracy Merlin, Australia
Cammile Schubert, Australia

WS10: Capacity building in agencies for efficient and effective HTA

Carol Lefebvre, United Kingdom
Tom Jefferson, Italy
Carolyn Spry, Canada
Monika Mierzwinski-Urban, Canada
Danielle Rabb, Canada
Siw Waffenschmidt, Denmark
Deborah A. Zarin
Ghassan Karam, Switzerland
Dagmara Chojecki, Canada
Lisa Tjosvold, Canada

WS11: Analytical decision models for HTA: how to choose a distribution for my probabilistic sensitivity analysis? Examples from mental health data

Bjorn Hofmann, Norway
Ken Paterson, United Kingdom
Eric Low, United Kingdom
Lillie Shockney, USA
Mona Sabharwal, Canada
Sophie Staniszewska, United Kingdom
Sophie Werko, Sweden
Eibhlin Mulroe, Ireland

WS12: Measuring Utility for Health Technology Assessment Using EQ-5D and SF-6D Instruments

Luciane N.Cruz, Brazil Kenya M.Noronha, Brazil Monica V.Andrade, Brazil Suzi A.Camey, Brazil WS13: Developing a systematic approach to impact evaluation of publicly funded systems: examples from early awareness and alert systems

Sue L.Simpson, United Kingdom Claire Packer, United Kingdom Anna Nachtnebel, Australia Brendon Kearney, Austria Iñaki Gutiérrez-Ibarluzea, Spain Andra Morrison, Canada Marianne Klemp, Norway Laura Lintamo, Sweden

WS14: Maximising the value of Comparative Effectiveness Research for patient care in an era of economic uncertainty - a tale from two countries

Thomas D. Kenny, United Kingdom Joe Selby, USA Hilda Bastian, USA Stijn Tersmette, The Netherlands

DAY 3 - MONDAY, JUNE 16 (click here)

10:45 - 12:15

Panel 1 A step forward: integrating HTA in a consistent ecosystem

Speakers: Americo Cicchetti, Italy Laura Sampierto Colom, Spain

Alexandre Barna, France Risto Roine, Finland

Debjani Mueller, South Africa **Mitchell Sugarman**, USA

10:45 - 12:15

Panel 2 Adaptive Approaches to Licensing, HTA and Use of Technologies in Health

Care Systems, summary of proceedings from the HTAi Policy Forum

Speakers: Chris Henshall, United Kingdom

10:45 - 12:15

Panel 3 Decision rules for cost-effectiveness analysis in low - and middle - income

countries

Speakers: Rita Faria, United Kingdom Paul Revill, United Kingdom

Aurelio Mejia, Colombia Pritaporn Kingkaew, Thailand

Thomas Wilkinson, United Amanda Glassman, USA

Kingdom

10:45 - 12:15

The GRADE/DECIDE interactive Evidence to Decision (EtD) Framework: A Panel 4

Tool that can be used to help people go from HTAs (or other evidence

summaries) to decisions or recommendations

Gro Jamtvedt, Norway Marianne Klemp, Norway Speakers:

Shaun Trewweek, United

Kingdom

Sarah Rosenbaum, Norway

10:45 - 12:15

Panel 5 The use of Patient Reported Outcomes (PROs) to assess treatment effects in

rare diseases

Speakers: Patricia A Miller, Canada Gordon Guyatt, Canada

Sohail Mulla, Canada

13:45 - 15:15

Panel 6 How to different HTA approaches conceptualize and measure the

components of "value"?

Steven Pearson, USA Speakers: Meindert Boysen, United Kingdom

> Bobby Dubois, USA Kim Bailey, USA

James Murray, USA

13:45 - 15:15

Panel 7 Establishing Early Dialogue between Industry and HTA Agencies:

Perspectives of INAHTA Members, NICE and Industry

Speakers: Terri O'Grady, Canada Brian O'Rourke, Canada

Iñaki Gutiérrez-Ibarluzea, Spain Adiran Griffin, United Kingdom

François Meyer, France **Nick Crabb**, United Kingdom

13:45 - 15:15

Panel 8 Improving the quality of decisions around the public funding of new health

technologies: the value of disease-specific (reference) models

Speakers: Hossein Afzali, Australia Jane Kim, USA

Erik Dasbach, USA Geert Frederix, The Netherlands

Natasha Stout, USA

13:45 - 15:15

Panel 9 Integrating ethics in HTA - methods and merits

Speakers: Bjørn Hofmann, Norway Gert Jan van der Wilt,

Netherlands

Ken Bond, Canada **Wija Oortwijn**, Netherlands

Dario Sacchini, Italy

13:45 - 15:15

Panel 10 The value of patient involvement in HTA - what are the means to reach the full

potential?

Speakers: Camilla Palmhøj Nielsen, Karen Facey, United Kingdom

Denmark

Nancy Davenport - Ennis, USA Kenneth Patterson, United

Kingdom

15:45 - 17:15

Panel 11 Medical Devices: Are Different HTA Approaches Really Needed?

Speakers: Mirella Marlow, United Kingdom Les Levin, Canada

Markus Siebert, Belgium Oriana Ciani, United Kingdom

15:45 - 17:15

Panel 12 First experiences with the EUnetHTA joint rapid relative effectiveness

assessment; The Zostavax case

Speakers: Andrea Rappagliosi, France Lidia Becla, The Netherlands

Finn Borlum Kristensen, Ingrid Zechmeister, Austria

Denmark

Po Kam Cheung, The

Netherlands

15:45 - 17:15

Panel 13 Introducing the Gates Reference Case

Speakers: Thomas Wilkinson, United Damian Walker, USA

Kingdom

Peter Neumann, USA Paul Revill, United Kingdom

15:45 - 17:15

Panel 14 Strategies for Moving Evidence into Action by Multiple Stakeholders

Speakers: Daniel Alan Ollendorf, USA Donald Goldmann, USA

Barbra Rabson, USA Wim Goettsch, The Netherlands

15:45 - 17:15

Panel 15 Executing a Global Patient-Centered Research Agenda: Lessons Learned

from Establishing PCORI

Speakers: David Grainger, Australia Tony Coelho, USA

Marc Boutin, USA Chris Henshall, United Kingdom

Durhane Wong-Rieger, Canada

DAY 4 - TUESDAY, JUNE 17 (click here)

10:45 - 12:15

Panel 16 Early dialogue with stakeholders crucial for enhancing the implementation of

innovations. Current experiences and future developments from the

perspective of Early Awareness and Alert Systems

Speakers: Inaki Gutierrez-Ibarluzea, Spain Hans-Peter Dauben, Germany

Cederic Jehanno, Canada Alexandre Barna, France

10:45 - 12:15

Panel 17 Coverage with evidence development: UK and USA approaches

Speakers: Hannah Patrick, United Kingdom Louis Jacques, USA

Mirella Marlow, United Kingdom Andrew Farb, USA

10:45 - 12:15

Panel 18 NICE & Value Based Assessment; impact on transferability, predictability and

utility

Speakers: Christopher Paul O'Regan, United Finn Børlum Kristensen,

Kingdom Denmark

Janet Wale, Australia Meindert Boysen, United

Kingdom

Matthew Brougham, Canada Anne Lee, United Kingdom

10:45 - 12:15

Panel 19 MCDA across the decision-making continuum: feedback and reflection from

the field

Speakers: Mireille M. Goetghebeur, Canada Wim Goettsch, Netherlands

Alaa Hamed, USA Sitaporn Youngkong, Thailand

François Meyer, France Janet Martin, Canada

10:45 - 12:15

Panel 20 Scoping as a means to systematically involve patients and public in Health

Technology Assessment (HTA)

Speakers: Gert Jan van der Wilt, The James B Chilcott, United

Netherlands Kingdom

Kristin Bakke Lysdahl, Norway Dario Sacchini, Italy

Kati Mozygemba, Germany

15:45 - 17:15

Panel 21 Horizon Scanning: Likely to stifle or enhance adoption of innovations in

health care?

Speakers: Karen Schoelles, USA Elise Berliner, USA

Paula Chakravarti, USA Jeff Thompson, USA

Hussein Noorani, USA

15:45 - 17:15

Panel 22 Innovation and HTA: Paying for value.... and for uncertainty?

Speakers: Sarah Garner, United Kingdom Dima Samaha, Canada

Wim Goettsch, The Netherlands Jens Grueger, Switzerland

15:45 - 17:15

Panel 23 Challenges in Transferring HTAs from Setting to Setting

Speakers: Michael Drummond, United Kingdom Thomas Wilkinson, United

Kingdom

Andres Pichon-Riviere, Argentina Sachin Kamal-Bahl, USA

15:45 - 17:15

Panel 24 Don't forget about ethics! Context-specific approaches to ethical analysis in

Health Technology Assessments

Speakers: Emelie Heintz, Sweden Lars Sandman, Sweden

Sigrid Droste, Germany Iñaki Gutierrez Ibarluzea,

Sweden

Clémence Thebaut, France Bjørn Hofmann, Norway

Panel 25 Coverage with Evidence Development (CED) for Non-Drug Interventions -

Promises and Truths

Speakers: Urs Bruegger, Switzerland Christopher Henshall, United

Kingdom

Matthias Perleth, Germany Les Levin, Canada

Louis Jacques, USA Robyn Ward, Australia

DAY 5 - WEDNESDAY, JUNE 18 (click here)

9:00 - 10:30

Panel 26 Developing relative effectiveness estimates for medicines in development: a

shared framework based on collaboration across stakeholders. Insights from

the IMI GetReal Consortium

Speakers: Mike Chambers, United Kingdom Sarah Garner, United Kingdom

9:00 - 10:30

Panel 27 A new reality for new technologies assessed by HTA bodies and implication

for patient access: presentation of the case of Renal Denervation therapy

Speakers: Chris Henshall, United Kingdom Matthieu Couche, Switzerland

Tove Ringerike, Norway **Inaki Gutierrez**, Spain

Brendon Kearney, Australia Sebastian Gaiser, Belgium

9:00 - 10:30

Panel 28 "Same, same but different!": HTA in and for hospitals

Speakers: Claudia Wild, Australia

9:00 - 10:30

Panel 29 Accessing unpublished evidence - issues around trails registers and

regulatory agency data

Speakers: Carol Lefebvre, United Kingdom Beate Wieseler, Germany

Tom Jefferson, Italy Deborah Zarin, USA

9:00 - 10:30

Panel 30 Optimizing Treatment Sequence and Priority Decisions in Oncology:

Developing Methodologic Guidance for Improved Outcomes and Resource

Efficiency

Speakers: Sean Tunis, USA Anne Schott, USA

Michael Kolodziej, USA Bhakti Arondekar, USA

9:00 - 10:30

Panel 31 Using HTA in China: From Strengthening Patient-centered Care to Enhancing

Health System Performance

Speakers: Yingyao Chen, China Di Xue, China

Hengjin Dong, China Lizheng Shi, USA

Raymond Pong, Canada

9:00 - 10:30

Panel 32 Quality Standards for Patient Involvement in HTA

Speakers: Karen Facey, United Kingdom Moira Howie, United Kingdom

Eric Low, United Kingdom Newell E McElwee, USA

Brian O'Rourke, Canada

ranei 33	Infections in Different Regions around the World
Speakers:	Laura J Goldstein, Canada

^{*}Please note that the program is subject to change.